{
  "armOrCohorts" : [ {
    "armAccession" : "ARM1",
    "description" : "Placebo omalizumab pre-treatment, placebo RIT, placebo omalizumab + placebo IT",
    "name" : "Placebo Immunotherapy with placebo anti-IgE",
    "typeReported" : null,
    "typePreferred" : null,
    "subjectcnt" : null
  }, {
    "armAccession" : "ARM2",
    "description" : "Placebo omalizumab pre-treatment, ragweed RIT, placebo omalizumab + ragweed IT",
    "name" : "Immunotherapy with placebo anti-IgE",
    "typeReported" : null,
    "typePreferred" : null,
    "subjectcnt" : null
  }, {
    "armAccession" : "ARM3",
    "description" : "Omalizumab pre-treatment, placebo RIT, omalizumab + placebo IT",
    "name" : "Placebo Immunotherapy with anti-IgE",
    "typeReported" : null,
    "typePreferred" : null,
    "subjectcnt" : null
  }, {
    "armAccession" : "ARM4",
    "description" : "Omalizumab pre-treatment, ragweed RIT, omalizumab + ragweed IT",
    "name" : "Immunotherapy with anti-IgE",
    "typeReported" : null,
    "typePreferred" : null,
    "subjectcnt" : null
  } ],
  "inclusionExclusions" : [ {
    "criterionAccession" : "CRIT1",
    "criterionCategory" : "Inclusion",
    "criterion" : "Able to comprehend and grant a witnessed, written informed consent prior to any study procedures."
  }, {
    "criterionAccession" : "CRIT10",
    "criterionCategory" : "Inclusion",
    "criterion" : "Participants must have a baseline serum IgE level > 10 and < 700 IU/mL."
  }, {
    "criterionAccession" : "CRIT11",
    "criterionCategory" : "Exclusion",
    "criterion" : "Participants < 30 kg or > 120 kg."
  }, {
    "criterionAccession" : "CRIT12",
    "criterionCategory" : "Exclusion",
    "criterion" : "Participants who are pregnant or lactating."
  }, {
    "criterionAccession" : "CRIT13",
    "criterionCategory" : "Exclusion",
    "criterion" : "Participants with a history of severe anaphylactoid (non-IgE mediated) or anaphylactic reaction(s)."
  }, {
    "criterionAccession" : "CRIT14",
    "criterionCategory" : "Exclusion",
    "criterion" : "Participants with a history of immunotherapy within the past 10 years, if received one full year of immunotherapy, or within the past 5 years if received less than one year of immunotherapy."
  }, {
    "criterionAccession" : "CRIT15",
    "criterionCategory" : "Exclusion",
    "criterion" : "Participants with known hypersensitivity to trial rescue medication (fexofenadine HCl)."
  }, {
    "criterionAccession" : "CRIT16",
    "criterionCategory" : "Exclusion",
    "criterion" : "Participants taking beta-adrenergic antagonists in any form."
  }, {
    "criterionAccession" : "CRIT17",
    "criterionCategory" : "Exclusion",
    "criterion" : "Participants taking allergic ophthalmologic medication."
  }, {
    "criterionAccession" : "CRIT18",
    "criterionCategory" : "Exclusion",
    "criterion" : "Participants with clinically significant perennial rhinitis that would interfere in assessment of ragweed-induced seasonal allergic rhinitis symptoms."
  }, {
    "criterionAccession" : "CRIT19",
    "criterionCategory" : "Exclusion",
    "criterion" : "Presence of a severely deviated nasal septum, septal perforation, structural nasal defect or large nasal polyps causing obstruction."
  }, {
    "criterionAccession" : "CRIT2",
    "criterionCategory" : "Inclusion",
    "criterion" : "Male or female 18 to 50 years of age."
  }, {
    "criterionAccession" : "CRIT20",
    "criterionCategory" : "Exclusion",
    "criterion" : "History of an upper respiratory or sinus infection requiring treatment with an antibiotic within 2 weeks prior to Visit -01."
  }, {
    "criterionAccession" : "CRIT21",
    "criterionCategory" : "Exclusion",
    "criterion" : "Documented evidence of acute or significant chronic sinusitis, as determined by the Investigator."
  }, {
    "criterionAccession" : "CRIT22",
    "criterionCategory" : "Exclusion",
    "criterion" : "Asthma (either history of, abnormal spirometry, [FEV1 <80% predicted] or use of asthma medications)."
  }, {
    "criterionAccession" : "CRIT23",
    "criterionCategory" : "Exclusion",
    "criterion" : "Chronic or intermittent use of inhaled, oral, intra-muscular, or intra-venous corticosteroids; or chronic or intermittent use of topical corticosteroids within 4 weeks of Visit -01."
  }, {
    "criterionAccession" : "CRIT24",
    "criterionCategory" : "Exclusion",
    "criterion" : "Chronic use of medications (e.g., tricyclic antidepressants) that would affect assessment of the effectiveness of the study medication."
  }, {
    "criterionAccession" : "CRIT25",
    "criterionCategory" : "Exclusion",
    "criterion" : "Rhinitis medicamentosa."
  }, {
    "criterionAccession" : "CRIT26",
    "criterionCategory" : "Exclusion",
    "criterion" : "History or presence of significant renal, hepatic, neurologic, cardiovascular, hematologic, metabolic, cerebrovascular, respiratory, gastrointestinal or other significant medical condition including, autoimmune or collagen vascular disorders, aside from organ-specific autoimmune disease limited to the thyroid that in the Investigator?s opinion could interfere with the study or require medical treatment that would interfere with the study."
  }, {
    "criterionAccession" : "CRIT27",
    "criterionCategory" : "Exclusion",
    "criterion" : "History of cancer other than basal cell carcinoma of the skin."
  }, {
    "criterionAccession" : "CRIT28",
    "criterionCategory" : "Exclusion",
    "criterion" : "History within the past year of excessive alcohol intake or drug addiction."
  }, {
    "criterionAccession" : "CRIT29",
    "criterionCategory" : "Exclusion",
    "criterion" : "Current smokers, greater than 10 pack year history, or participants who quit smoking less than one year prior to Screening."
  }, {
    "criterionAccession" : "CRIT3",
    "criterionCategory" : "Inclusion",
    "criterion" : "Female participants of child bearing age must have a negative urine pregnancy test at Visit -01 and a negative urine pregnancy test at subsequent visits. In addition, female participants must be using a medically acceptable form of birth control."
  }, {
    "criterionAccession" : "CRIT30",
    "criterionCategory" : "Exclusion",
    "criterion" : "Use of any prohibited concomitant medications during the washout period (i.e., before screening) and throughout the study period."
  }, {
    "criterionAccession" : "CRIT31",
    "criterionCategory" : "Exclusion",
    "criterion" : "Participants currently undergoing immunotherapy."
  }, {
    "criterionAccession" : "CRIT32",
    "criterionCategory" : "Exclusion",
    "criterion" : "Participants with clinically significant abnormality on 12-lead ECG on screening visit."
  }, {
    "criterionAccession" : "CRIT33",
    "criterionCategory" : "Exclusion",
    "criterion" : "Treatment with an experimental, non-approved drug, or investigational drug within the past 30 days."
  }, {
    "criterionAccession" : "CRIT34",
    "criterionCategory" : "Exclusion",
    "criterion" : "Participants with a history of noncompliance to medical regimens and participants who are considered potentially unreliable."
  }, {
    "criterionAccession" : "CRIT35",
    "criterionCategory" : "Exclusion",
    "criterion" : "Previous treatment with a monoclonal antibody for any reason including anti-IgE in any form (e.g., omalizumab)."
  }, {
    "criterionAccession" : "CRIT36",
    "criterionCategory" : "Exclusion",
    "criterion" : "Participants with known hypersensitivity to trial drug ingredients (i.e., sucrose, histidine, polysorbate 20) or related drugs (i.e., monoclonal antibody; polyclonal gamma-globulin)."
  }, {
    "criterionAccession" : "CRIT4",
    "criterionCategory" : "Inclusion",
    "criterion" : "History of seasonal allergic rhinitis for at least 2 years with symptoms during the ragweed pollen season requiring pharmacotherapy."
  }, {
    "criterionAccession" : "CRIT5",
    "criterionCategory" : "Inclusion",
    "criterion" : "A positive skin test by prick method to ragweed pollen at Visit -01. A positive skin prick test will be defined as a ragweed pollen-induced wheal >3 mm larger in diameter than diluent control (measurements will be made 15-20 minutes after application)."
  }, {
    "criterionAccession" : "CRIT6",
    "criterionCategory" : "Inclusion",
    "criterion" : "Must be capable of faithfully completing the diary and of attending regularly scheduled study visits."
  }, {
    "criterionAccession" : "CRIT7",
    "criterionCategory" : "Inclusion",
    "criterion" : "Must intend to remain in the ragweed pollen area during the entire ragweed season."
  }, {
    "criterionAccession" : "CRIT8",
    "criterionCategory" : "Inclusion",
    "criterion" : "Willing to avoid prohibited medications for the periods indicated in the protocol."
  }, {
    "criterionAccession" : "CRIT9",
    "criterionCategory" : "Inclusion",
    "criterion" : "Participants must meet pretrial eligibility requirements for trial enrollment (acceptable medical history, physical examination results, normal electrocardiogram and acceptable laboratory test results)."
  } ],
  "protocols" : [ {
    "protocolAccession" : "PTL2333",
    "type" : "Assay",
    "description" : null,
    "fileName" : "Apop_panel_definition.PTL2333.xls",
    "name" : "Apoptosis",
    "originalFileName" : "Apop_panel_definition.xls"
  }, {
    "protocolAccession" : "PTL2331",
    "type" : "Clinical Study Protocol",
    "description" : null,
    "fileName" : "Casale ITN019AD Protocol v8.0.PTL2331.pdf",
    "name" : "Clinical",
    "originalFileName" : "Casale ITN019AD Protocol v8.0.pdf"
  }, {
    "protocolAccession" : "PTL2334",
    "type" : "Assay",
    "description" : "Processing the biosamples and experiment samples, incubation with detection antibody, SA-HRP reaction, stopping the reaction, and scanning the plate.",
    "fileName" : "PlaceholderProtocol.PTL2334.doc",
    "name" : "ELISA_protocol",
    "originalFileName" : "PlaceholderProtocol.doc"
  }, {
    "protocolAccession" : "PTL2332",
    "type" : "Assay",
    "description" : null,
    "fileName" : "Flow_panel_definition.PTL2332.xls",
    "name" : "Flow Surface",
    "originalFileName" : "Flow_panel_definition.xls"
  }, {
    "protocolAccession" : "PTL2695",
    "type" : "Case Report Form",
    "description" : "This document contains all the case report forms for the ITN019AD Study Allergen immunotherapy Co-administered with Omalizumab.",
    "fileName" : "Casale-Unannotated-CRF-FINAL.PTL2695.pdf",
    "name" : "ITN019AD Casale Case Report Forms",
    "originalFileName" : "Casale-Unannotated-CRF-FINAL.pdf"
  } ],
  "plannedVisits" : [ {
    "plannedVisitAccession" : "PV65",
    "name" : "SDY1.Visit_-1.Screening.Week_-12.Protocol Day_-84.Plan Visit Min Day_-25.Plan Visit Max Day_-4",
    "range" : "-25.0 to -19.0"
  }, {
    "plannedVisitAccession" : "PV66",
    "name" : "SDY1.Visit_-1.Screening.Week_-10.Protocol Day_-70.Plan Visit Min Day_-18.Plan Visit Max Day_-1",
    "range" : "-18.0 to -1.0"
  }, {
    "plannedVisitAccession" : "PV67",
    "name" : "SDY1.Visit_0.Screening.Week_-11.Protocol Day_-77.Plan Visit Min Day_1.Plan Visit Max Day_1",
    "range" : "1.0 to 1.0"
  }, {
    "plannedVisitAccession" : "PV68",
    "name" : "SDY1.Visit_0.Screening.Week_-9.Protocol Day_-63.Plan Visit Min Day_11.Plan Visit Max Day_19",
    "range" : "11.0 to 19.0"
  }, {
    "plannedVisitAccession" : "PV69",
    "name" : "SDY1.Visit_1.Omalizumab Pre-treatment.Week_-9.Protocol Day_-63.Plan Visit Min Day_25.Plan Visit Max Day_33",
    "range" : "25.0 to 33.0"
  }, {
    "plannedVisitAccession" : "PV70",
    "name" : "SDY1.Visit_2.Omalizumab Pre-treatment.Week_-5.Protocol Day_-35.Plan Visit Min Day_39.Plan Visit Max Day_47",
    "range" : "39.0 to 47.0"
  }, {
    "plannedVisitAccession" : "PV71",
    "name" : "SDY1.Visit_3.Omalizumab Pre-treatment.Week_-1.Protocol Day_-7.Plan Visit Min Day_53.Plan Visit Max Day_61",
    "range" : "53.0 to 59.0"
  }, {
    "plannedVisitAccession" : "PV72",
    "name" : "SDY1.Visit_4.RIT.Week_0.Protocol Day_0.Plan Visit Min Day_60.Plan Visit Max Day_68",
    "range" : "60.0 to 66.0"
  }, {
    "plannedVisitAccession" : "PV73",
    "name" : "SDY1.Visit_5.Omalizumab/Placebo+Immunotherapy/Placebo.Week_1.Protocol Day_7.Plan Visit Min Day_67.Plan Visit Max Day_75",
    "range" : "67.0 to 73.0"
  }, {
    "plannedVisitAccession" : "PV74",
    "name" : "SDY1.Visit_6.Omalizumab/Placebo+Immunotherapy/Placebo.Week_2.Protocol Day_14.Plan Visit Min Day_74.Plan Visit Max Day_82",
    "range" : "74.0 to 80.0"
  }, {
    "plannedVisitAccession" : "PV75",
    "name" : "SDY1.Visit_7.Omalizumab/Placebo+Immunotherapy/Placebo.Week_3.Protocol Day_21.Plan Visit Min Day_81.Plan Visit Max Day_89",
    "range" : "81.0 to 87.0"
  }, {
    "plannedVisitAccession" : "PV76",
    "name" : "SDY1.Visit_8.Omalizumab/Placebo+Immunotherapy/Placebo.Week_4.Protocol Day_28.Plan Visit Min Day_88.Plan Visit Max Day_96",
    "range" : "88.0 to 94.0"
  }, {
    "plannedVisitAccession" : "PV77",
    "name" : "SDY1.Visit_9.Omalizumab/Placebo+Immunotherapy/Placebo.Week_5.Protocol Day_35.Plan Visit Min Day_95.Plan Visit Max Day_103",
    "range" : "95.0 to 101.0"
  }, {
    "plannedVisitAccession" : "PV78",
    "name" : "SDY1.Visit_10.Omalizumab/Placebo+Immunotherapy/Placebo.Week_6.Protocol Day_42.Plan Visit Min Day_102.Plan Visit Max Day_110",
    "range" : "102.0 to 107.0"
  }, {
    "plannedVisitAccession" : "PV79",
    "name" : "SDY1.Visit_11.Omalizumab/Placebo+Immunotherapy/Placebo.Week_7.Protocol Day_49.Plan Visit Min Day_109.Plan Visit Max Day_117",
    "range" : "109.0 to 115.0"
  }, {
    "plannedVisitAccession" : "PV80",
    "name" : "SDY1.Visit_12.Omalizumab/Placebo+Immunotherapy/Placebo.Week_8.Protocol Day_56.Plan Visit Min Day_116.Plan Visit Max Day_124",
    "range" : "116.0 to 122.0"
  }, {
    "plannedVisitAccession" : "PV81",
    "name" : "SDY1.Visit_13.Omalizumab/Placebo+Immunotherapy/Placebo.Week_9.Protocol Day_63.Plan Visit Min Day_123.Plan Visit Max Day_131",
    "range" : "123.0 to 129.0"
  }, {
    "plannedVisitAccession" : "PV82",
    "name" : "SDY1.Visit_14.Omalizumab/Placebo+Immunotherapy/Placebo.Week_10.Protocol Day_70.Plan Visit Min Day_130.Plan Visit Max Day_138",
    "range" : "130.0 to 136.0"
  }, {
    "plannedVisitAccession" : "PV83",
    "name" : "SDY1.Visit_15.Omalizumab/Placebo+Immunotherapy/Placebo.Week_11.Protocol Day_77.Plan Visit Min Day_137.Plan Visit Max Day_145",
    "range" : "137.0 to 143.0"
  }, {
    "plannedVisitAccession" : "PV84",
    "name" : "SDY1.Visit_16.Omalizumab/Placebo+Immunotherapy/Placebo.Week_12.Protocol Day_84.Plan Visit Min Day_144.Plan Visit Max Day_152",
    "range" : "144.0 to 150.0"
  }, {
    "plannedVisitAccession" : "PV85",
    "name" : "SDY1.Visit_17.Follow-up (2003 ragweed season).Week_13.Protocol Day_91.Plan Visit Min Day_151.Plan Visit Max Day_159",
    "range" : "151.0 to 159.0"
  }, {
    "plannedVisitAccession" : "PV86",
    "name" : "SDY1.Visit_18.Follow-up (2003 ragweed season).Week_19.Protocol Day_133.Plan Visit Min Day_193.Plan Visit Max Day_211",
    "range" : "193.0 to 211.0"
  }, {
    "plannedVisitAccession" : "PV87",
    "name" : "SDY1.Visit_19.Follow-up (2003 ragweed season).Week_31.Protocol Day_217.Plan Visit Min Day_291.Plan Visit Max Day_299",
    "range" : "291.0 to 299.0"
  }, {
    "plannedVisitAccession" : "PV88",
    "name" : "SDY1.Visit_20.Follow-up (2003 ragweed season).Week_43.Protocol Day_301.Plan Visit Min Day_375.Plan Visit Max Day_383",
    "range" : "375.0 to 383.0"
  }, {
    "plannedVisitAccession" : "PV89",
    "name" : "SDY1.Visit_21.Extended Follow-up (2004 ragweed season).Week_55.Protocol Day_385.Plan Visit Min Day_459.Plan Visit Max Day_467",
    "range" : "459.0 to 467.0"
  }, {
    "plannedVisitAccession" : "PV90",
    "name" : "SDY1.Visit_22.Extended Follow-up (2004 ragweed season).Week_57.Protocol Day_399.Plan Visit Min Day_473.Plan Visit Max Day_480",
    "range" : "473.0 to 480.0"
  }, {
    "plannedVisitAccession" : "PV91",
    "name" : "SDY1.Visit_23.Extended Follow-up (2004 ragweed season).Week_59.Protocol Day_413.Plan Visit Min Day_487.Plan Visit Max Day_495",
    "range" : "487.0 to 495.0"
  }, {
    "plannedVisitAccession" : "PV92",
    "name" : "SDY1.Visit_24.Extended Follow-up (2004 ragweed season).Week_61.Protocol Day_427.Plan Visit Min Day_501.Plan Visit Max Day_515",
    "range" : "501.0 to 514.0"
  }, {
    "plannedVisitAccession" : "PV93",
    "name" : "SDY1.Visit_25.Extended Follow-up (2004 ragweed season).Week_63.Protocol Day_441.Plan Visit Min Day_515.Plan Visit Max Day_523",
    "range" : "515.0 to 523.0"
  }, {
    "plannedVisitAccession" : "PV94",
    "name" : "SDY1.Visit_26.Extended Follow-up (2004 ragweed season).Week_65.Protocol Day_455.Plan Visit Min Day_529.Plan Visit Max Day_537",
    "range" : "529.0 to 537.0"
  }, {
    "plannedVisitAccession" : "PV95",
    "name" : "SDY1.Visit_27.Extended Follow-up (2004 ragweed season).Week_67.Protocol Day_469.Plan Visit Min Day_543.Plan Visit Max Day_551",
    "range" : "543.0 to 551.0"
  }, {
    "plannedVisitAccession" : "PV96",
    "name" : "SDY1.Visit_28.Extended Follow-up (2004 ragweed season).Week_71.Protocol Day_497.Plan Visit Min Day_561.Plan Visit Max Day_569",
    "range" : "561.0 to 569.0"
  }, {
    "plannedVisitAccession" : "PV3080",
    "name" : "Samples without study time information",
    "range" : "570.0 to 570.0"
  } ],
  "assessmentPlannedVisits" : [ {
    "id" : {
      "studyAccession" : "SDY1",
      "accession" : "AP69978"
    },
    "pivotTable" : "assessment_panel",
    "accessionNum" : 69978,
    "name" : "15 mins post injection allergy skin reaction measurement",
    "plannedVisitAccessions" : "PV3080; PV65; PV66; PV67; PV68; PV69; PV70; PV71; PV72; PV73; PV74; PV75; PV76; PV77; PV78; PV79; PV80; PV81; PV82; PV83; PV84; PV85; PV86; PV87; PV88; PV89; PV90; PV91; PV92; PV93; PV94; PV95; PV96",
    "plannedVisitCounts" : "0; 0; 0; 0; 0; 0; 0; 0; 0; 0; 0; 0; 0; 0; 0; 0; 0; 0; 0; 0; 0; 0; 0; 0; 0; 0; 0; 0; 0; 0; 0; 0; 0"
  }, {
    "id" : {
      "studyAccession" : "SDY1",
      "accession" : "AP69979"
    },
    "pivotTable" : "assessment_panel",
    "accessionNum" : 69979,
    "name" : "24 hrs post injection allergy skin reaction measurement",
    "plannedVisitAccessions" : "PV3080; PV65; PV66; PV67; PV68; PV69; PV70; PV71; PV72; PV73; PV74; PV75; PV76; PV77; PV78; PV79; PV80; PV81; PV82; PV83; PV84; PV85; PV86; PV87; PV88; PV89; PV90; PV91; PV92; PV93; PV94; PV95; PV96",
    "plannedVisitCounts" : "0; 0; 0; 0; 0; 0; 0; 0; 0; 0; 0; 0; 0; 0; 0; 0; 0; 0; 0; 0; 0; 0; 0; 0; 0; 0; 0; 0; 0; 0; 0; 0; 0"
  }, {
    "id" : {
      "studyAccession" : "SDY1",
      "accession" : "AP72352"
    },
    "pivotTable" : "assessment_panel",
    "accessionNum" : 72352,
    "name" : "Allergen History",
    "plannedVisitAccessions" : "PV3080; PV65; PV66; PV67; PV68; PV69; PV70; PV71; PV72; PV73; PV74; PV75; PV76; PV77; PV78; PV79; PV80; PV81; PV82; PV83; PV84; PV85; PV86; PV87; PV88; PV89; PV90; PV91; PV92; PV93; PV94; PV95; PV96",
    "plannedVisitCounts" : "0; 0; 0; 0; 0; 0; 0; 0; 0; 0; 0; 0; 0; 0; 0; 0; 0; 0; 0; 0; 0; 0; 0; 0; 0; 0; 0; 0; 0; 0; 0; 0; 0"
  }, {
    "id" : {
      "studyAccession" : "SDY1",
      "accession" : "AP72353"
    },
    "pivotTable" : "assessment_panel",
    "accessionNum" : 72353,
    "name" : "Allergy Symptom History",
    "plannedVisitAccessions" : "PV3080; PV65; PV66; PV67; PV68; PV69; PV70; PV71; PV72; PV73; PV74; PV75; PV76; PV77; PV78; PV79; PV80; PV81; PV82; PV83; PV84; PV85; PV86; PV87; PV88; PV89; PV90; PV91; PV92; PV93; PV94; PV95; PV96",
    "plannedVisitCounts" : "0; 0; 0; 0; 0; 0; 0; 0; 0; 0; 0; 0; 0; 0; 0; 0; 0; 0; 0; 0; 0; 0; 0; 0; 0; 0; 0; 0; 0; 0; 0; 0; 0"
  }, {
    "id" : {
      "studyAccession" : "SDY1",
      "accession" : "AP72193"
    },
    "pivotTable" : "assessment_panel",
    "accessionNum" : 72193,
    "name" : "Animal Exposure History",
    "plannedVisitAccessions" : "PV3080; PV65; PV66; PV67; PV68; PV69; PV70; PV71; PV72; PV73; PV74; PV75; PV76; PV77; PV78; PV79; PV80; PV81; PV82; PV83; PV84; PV85; PV86; PV87; PV88; PV89; PV90; PV91; PV92; PV93; PV94; PV95; PV96",
    "plannedVisitCounts" : "0; 0; 0; 0; 0; 0; 0; 0; 0; 0; 0; 0; 0; 0; 0; 0; 0; 0; 0; 0; 0; 0; 0; 0; 0; 0; 0; 0; 0; 0; 0; 0; 0"
  }, {
    "id" : {
      "studyAccession" : "SDY1",
      "accession" : "AP69819"
    },
    "pivotTable" : "assessment_panel",
    "accessionNum" : 69819,
    "name" : "Food Allergy History",
    "plannedVisitAccessions" : "PV3080; PV65; PV66; PV67; PV68; PV69; PV70; PV71; PV72; PV73; PV74; PV75; PV76; PV77; PV78; PV79; PV80; PV81; PV82; PV83; PV84; PV85; PV86; PV87; PV88; PV89; PV90; PV91; PV92; PV93; PV94; PV95; PV96",
    "plannedVisitCounts" : "0; 0; 0; 0; 0; 0; 0; 0; 0; 0; 0; 0; 0; 0; 0; 0; 0; 0; 0; 0; 0; 0; 0; 0; 0; 0; 0; 0; 0; 0; 0; 0; 0"
  }, {
    "id" : {
      "studyAccession" : "SDY1",
      "accession" : "AP72034"
    },
    "pivotTable" : "assessment_panel",
    "accessionNum" : 72034,
    "name" : "Immunotherapy History",
    "plannedVisitAccessions" : "PV3080; PV65; PV66; PV67; PV68; PV69; PV70; PV71; PV72; PV73; PV74; PV75; PV76; PV77; PV78; PV79; PV80; PV81; PV82; PV83; PV84; PV85; PV86; PV87; PV88; PV89; PV90; PV91; PV92; PV93; PV94; PV95; PV96",
    "plannedVisitCounts" : "0; 0; 0; 0; 0; 0; 0; 0; 0; 0; 0; 0; 0; 0; 0; 0; 0; 0; 0; 0; 0; 0; 0; 0; 0; 0; 0; 0; 0; 0; 0; 0; 0"
  }, {
    "id" : {
      "studyAccession" : "SDY1",
      "accession" : "AP72354"
    },
    "pivotTable" : "assessment_panel",
    "accessionNum" : 72354,
    "name" : "Other Allergy History",
    "plannedVisitAccessions" : "PV3080; PV65; PV66; PV67; PV68; PV69; PV70; PV71; PV72; PV73; PV74; PV75; PV76; PV77; PV78; PV79; PV80; PV81; PV82; PV83; PV84; PV85; PV86; PV87; PV88; PV89; PV90; PV91; PV92; PV93; PV94; PV95; PV96",
    "plannedVisitCounts" : "0; 0; 0; 0; 0; 0; 0; 0; 0; 0; 0; 0; 0; 0; 0; 0; 0; 0; 0; 0; 0; 0; 0; 0; 0; 0; 0; 0; 0; 0; 0; 0; 0"
  }, {
    "id" : {
      "studyAccession" : "SDY1",
      "accession" : "AP10000"
    },
    "pivotTable" : "assessment_panel",
    "accessionNum" : 10000,
    "name" : "Participant Diary Card Record",
    "plannedVisitAccessions" : "PV3080; PV65; PV66; PV67; PV68; PV69; PV70; PV71; PV72; PV73; PV74; PV75; PV76; PV77; PV78; PV79; PV80; PV81; PV82; PV83; PV84; PV85; PV86; PV87; PV88; PV89; PV90; PV91; PV92; PV93; PV94; PV95; PV96",
    "plannedVisitCounts" : "0; 0; 0; 0; 0; 0; 0; 0; 0; 0; 0; 0; 0; 0; 0; 0; 0; 0; 0; 0; 0; 0; 0; 0; 0; 0; 0; 0; 0; 0; 0; 0; 0"
  }, {
    "id" : {
      "studyAccession" : "SDY1",
      "accession" : "AP65065"
    },
    "pivotTable" : "assessment_panel",
    "accessionNum" : 65065,
    "name" : "Vital Signs",
    "plannedVisitAccessions" : "PV3080; PV65; PV66; PV67; PV68; PV69; PV70; PV71; PV72; PV73; PV74; PV75; PV76; PV77; PV78; PV79; PV80; PV81; PV82; PV83; PV84; PV85; PV86; PV87; PV88; PV89; PV90; PV91; PV92; PV93; PV94; PV95; PV96",
    "plannedVisitCounts" : "0; 159; 158; 159; 28; 156; 28; 154; 153; 150; 147; 147; 144; 145; 144; 145; 143; 144; 142; 143; 143; 148; 141; 139; 138; 85; 0; 0; 0; 0; 0; 0; 85"
  }, {
    "id" : {
      "studyAccession" : "SDY1",
      "accession" : "AP69670"
    },
    "pivotTable" : "assessment_panel",
    "accessionNum" : 69670,
    "name" : "Vital Signs Pre-injection (Ragweed)",
    "plannedVisitAccessions" : "PV3080; PV65; PV66; PV67; PV68; PV69; PV70; PV71; PV72; PV73; PV74; PV75; PV76; PV77; PV78; PV79; PV80; PV81; PV82; PV83; PV84; PV85; PV86; PV87; PV88; PV89; PV90; PV91; PV92; PV93; PV94; PV95; PV96",
    "plannedVisitCounts" : "0; 0; 0; 0; 0; 0; 0; 0; 0; 0; 0; 0; 0; 0; 0; 0; 0; 0; 0; 0; 0; 0; 0; 0; 0; 0; 0; 0; 0; 0; 0; 0; 0"
  }, {
    "id" : {
      "studyAccession" : "SDY1",
      "accession" : "AP69673"
    },
    "pivotTable" : "assessment_panel",
    "accessionNum" : 69673,
    "name" : "Vital Signs Pre-injection Histamine",
    "plannedVisitAccessions" : "PV3080; PV65; PV66; PV67; PV68; PV69; PV70; PV71; PV72; PV73; PV74; PV75; PV76; PV77; PV78; PV79; PV80; PV81; PV82; PV83; PV84; PV85; PV86; PV87; PV88; PV89; PV90; PV91; PV92; PV93; PV94; PV95; PV96",
    "plannedVisitCounts" : "0; 0; 0; 0; 0; 0; 0; 0; 0; 0; 0; 0; 0; 0; 0; 0; 0; 0; 0; 0; 0; 0; 0; 0; 0; 0; 0; 0; 0; 0; 0; 0; 0"
  } ],
  "experimentPlannedVisits" : [ {
    "id" : {
      "studyAccession" : "SDY1",
      "accession" : "EXP3727"
    },
    "pivotTable" : "experiment",
    "accessionNum" : 3727,
    "name" : "RPCIFLOW_ITN019AD",
    "plannedVisitAccessions" : "PV3080; PV65; PV66; PV67; PV68; PV69; PV70; PV71; PV72; PV73; PV74; PV75; PV76; PV77; PV78; PV79; PV80; PV81; PV82; PV83; PV84; PV85; PV86; PV87; PV88; PV89; PV90; PV91; PV92; PV93; PV94; PV95; PV96",
    "plannedVisitCounts" : "93; 0; 151; 0; 0; 0; 0; 0; 152; 145; 0; 0; 0; 140; 0; 0; 0; 144; 0; 0; 0; 144; 141; 139; 132; 0; 0; 0; 0; 0; 0; 0; 0"
  }, {
    "id" : {
      "studyAccession" : "SDY1",
      "accession" : "EXP14861"
    },
    "pivotTable" : "experiment",
    "accessionNum" : 14861,
    "name" : "Response to Free IgE, IgG-a Amb a, and IgG-a Ragweed",
    "plannedVisitAccessions" : "PV3080; PV65; PV66; PV67; PV68; PV69; PV70; PV71; PV72; PV73; PV74; PV75; PV76; PV77; PV78; PV79; PV80; PV81; PV82; PV83; PV84; PV85; PV86; PV87; PV88; PV89; PV90; PV91; PV92; PV93; PV94; PV95; PV96",
    "plannedVisitCounts" : "1; 5; 117; 0; 0; 0; 0; 28; 99; 103; 23; 6; 40; 69; 17; 3; 35; 76; 20; 3; 12; 106; 76; 69; 30; 25; 0; 0; 0; 0; 0; 0; 0"
  }, {
    "id" : {
      "studyAccession" : "SDY1",
      "accession" : "EXP14862"
    },
    "pivotTable" : "experiment",
    "accessionNum" : 14862,
    "name" : "IgM a Amb a1 response",
    "plannedVisitAccessions" : "PV3080; PV65; PV66; PV67; PV68; PV69; PV70; PV71; PV72; PV73; PV74; PV75; PV76; PV77; PV78; PV79; PV80; PV81; PV82; PV83; PV84; PV85; PV86; PV87; PV88; PV89; PV90; PV91; PV92; PV93; PV94; PV95; PV96",
    "plannedVisitCounts" : "0; 2; 31; 0; 0; 0; 0; 6; 31; 24; 1; 0; 0; 0; 0; 1; 9; 20; 2; 1; 1; 30; 2; 30; 30; 25; 0; 0; 0; 0; 0; 0; 0"
  }, {
    "id" : {
      "studyAccession" : "SDY1",
      "accession" : "EXP14863"
    },
    "pivotTable" : "experiment",
    "accessionNum" : 14863,
    "name" : "IgE-a Amb a response",
    "plannedVisitAccessions" : "PV3080; PV65; PV66; PV67; PV68; PV69; PV70; PV71; PV72; PV73; PV74; PV75; PV76; PV77; PV78; PV79; PV80; PV81; PV82; PV83; PV84; PV85; PV86; PV87; PV88; PV89; PV90; PV91; PV92; PV93; PV94; PV95; PV96",
    "plannedVisitCounts" : "1; 3; 85; 0; 0; 0; 0; 13; 56; 71; 21; 5; 22; 44; 16; 1; 21; 49; 16; 2; 11; 75; 56; 32; 0; 0; 0; 0; 0; 0; 0; 0; 0"
  }, {
    "id" : {
      "studyAccession" : "SDY1",
      "accession" : "EXP14864"
    },
    "pivotTable" : "experiment",
    "accessionNum" : 14864,
    "name" : "IgE-a Ragweed response",
    "plannedVisitAccessions" : "PV3080; PV65; PV66; PV67; PV68; PV69; PV70; PV71; PV72; PV73; PV74; PV75; PV76; PV77; PV78; PV79; PV80; PV81; PV82; PV83; PV84; PV85; PV86; PV87; PV88; PV89; PV90; PV91; PV92; PV93; PV94; PV95; PV96",
    "plannedVisitCounts" : "1; 3; 85; 0; 0; 0; 0; 13; 56; 71; 21; 5; 22; 44; 16; 1; 21; 49; 16; 2; 11; 75; 54; 32; 0; 0; 0; 0; 0; 0; 0; 0; 0"
  }, {
    "id" : {
      "studyAccession" : "SDY1",
      "accession" : "EXP14865"
    },
    "pivotTable" : "experiment",
    "accessionNum" : 14865,
    "name" : "IgG-a Ragweed response",
    "plannedVisitAccessions" : "PV3080; PV65; PV66; PV67; PV68; PV69; PV70; PV71; PV72; PV73; PV74; PV75; PV76; PV77; PV78; PV79; PV80; PV81; PV82; PV83; PV84; PV85; PV86; PV87; PV88; PV89; PV90; PV91; PV92; PV93; PV94; PV95; PV96",
    "plannedVisitCounts" : "0; 2; 31; 0; 0; 0; 0; 6; 30; 24; 1; 0; 0; 0; 0; 1; 9; 20; 2; 1; 1; 30; 2; 30; 30; 25; 0; 0; 0; 0; 0; 0; 0"
  }, {
    "id" : {
      "studyAccession" : "SDY1",
      "accession" : "EXP14866"
    },
    "pivotTable" : "experiment",
    "accessionNum" : 14866,
    "name" : "Response to IgG1-a Amb a1, and IgG4-a Amb a1",
    "plannedVisitAccessions" : "PV3080; PV65; PV66; PV67; PV68; PV69; PV70; PV71; PV72; PV73; PV74; PV75; PV76; PV77; PV78; PV79; PV80; PV81; PV82; PV83; PV84; PV85; PV86; PV87; PV88; PV89; PV90; PV91; PV92; PV93; PV94; PV95; PV96",
    "plannedVisitCounts" : "0; 0; 19; 0; 0; 0; 0; 3; 17; 14; 1; 0; 0; 0; 0; 0; 6; 12; 0; 1; 1; 17; 1; 16; 16; 14; 0; 0; 0; 0; 0; 0; 0"
  } ],
  "labTestPlannedVisits" : [ {
    "id" : {
      "studyAccession" : "SDY1",
      "accession" : "LP581"
    },
    "pivotTable" : "lab_test_panel",
    "accessionNum" : 581,
    "name" : "Blood Cell Count with Differential",
    "plannedVisitAccessions" : "PV3080; PV65; PV66; PV67; PV68; PV69; PV70; PV71; PV72; PV73; PV74; PV75; PV76; PV77; PV78; PV79; PV80; PV81; PV82; PV83; PV84; PV85; PV86; PV87; PV88; PV89; PV90; PV91; PV92; PV93; PV94; PV95; PV96",
    "plannedVisitCounts" : "0; 159; 0; 159; 0; 157; 0; 157; 0; 0; 0; 147; 0; 0; 0; 145; 0; 0; 0; 143; 0; 148; 0; 0; 137; 0; 0; 0; 0; 0; 0; 0; 0"
  }, {
    "id" : {
      "studyAccession" : "SDY1",
      "accession" : "LP1392"
    },
    "pivotTable" : "lab_test_panel",
    "accessionNum" : 1392,
    "name" : "Protein or Enzyme Type Measurement",
    "plannedVisitAccessions" : "PV3080; PV65; PV66; PV67; PV68; PV69; PV70; PV71; PV72; PV73; PV74; PV75; PV76; PV77; PV78; PV79; PV80; PV81; PV82; PV83; PV84; PV85; PV86; PV87; PV88; PV89; PV90; PV91; PV92; PV93; PV94; PV95; PV96",
    "plannedVisitCounts" : "0; 116; 43; 0; 0; 0; 0; 0; 0; 0; 0; 0; 0; 0; 0; 0; 0; 0; 0; 0; 0; 0; 0; 0; 0; 0; 0; 0; 0; 0; 0; 0; 0"
  } ]
}